Girodmedical has raised US$2 million
Girodmedical SAS has raised US$2 million on a first round of financing via Audacia SAS.
Girodmedical offers medical equipment and medical supplies online. These include massage tables, accessories and furniture, diagnostic equipment and accessories, anatomy models and physiology and anatomy books, medical uniforms and hygiene disinfection and protection products and disposable paper supplies. The company also provides surgical equipment, physiotherapy and rehabilitation products and fitness and sporting goods, comfort and well-being products (such as dental hygiene and aesthetic care) and assisted living products (such as big button phones and incontinence products). Girodmedical was incorporated in 2004 and is based in Nantes, France.
Oaklins’ team in France advised the shareholders of Girodmedical SAS on this transaction.
Talk to the deal team
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn morebioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Learn moreSLT has been acquired by Indutrade
SLT S.r.l. has been acquired by Indutrade AB and will be integrated into the group’s life science business area. The transaction is Indutrade’s fifth acquisition in 2025 and is expected to have a marginally positive impact on the group’s earnings per share.
Learn more